Liver Cancer Insights and Prevention Potential
A recent analysis published in The Lancet suggests that over 60% of liver cancers might be preventable. This is an eye-opening statistic, especially considering how significant liver cancer is on a global scale.
Currently, liver cancer ranks as the sixth most prevalent cancer worldwide, with about 870,000 new cases reported in 2022. Alarmingly, if trends continue, this number could soar to 1.52 million by 2050.
The primary driver behind liver cancer cases is viral infections, mainly the hepatitis B and C viruses. Hepatitis B, which can be vaccinated against, accounted for 39% of liver cancer cases in 2022. This percentage is forecasted to decrease slightly to 36.9% by 2025. Meanwhile, hepatitis C accounted for 29.1% of cases in the same year and is expected to decline to 25.9% by 2050.
On the flip side, liver cancers related to alcohol consumption and obesity are projected to rise over the next 25 years. Alcohol was responsible for 18.8% of liver cancer cases in 2022, projected to rise to 21.1% by 2050. Similarly, liver cancers tied to obesity-related diseases are expected to climb from 8% to 10.8% as obesity, diabetes, and high cholesterol continue to become more widespread.
Dr. Hashem El-Serag, a co-author of the report and chair of medicine at Baylor College of Medicine in Houston, noted that many individuals associate liver cancer primarily with alcohol use. “When people hear about cirrhosis, their first thought is often someone they know who drank heavily,” he pointed out. “But there’s a disconnect for many between MASLD, or fatty liver disease, and the risks of cirrhosis and liver cancer.”
MASLD, or metabolic dysfunction-associated steatotic liver disease, affects roughly 25% of American adults. It’s caused by fat accumulation in the liver, with about 5% experiencing a more severe form known as MASH, which significantly increases cancer risk.
Alcohol misuse also contributes to the risk of cirrhosis. Although liver cancer remains relatively uncommon in the U.S.—making up around 2.1% of new cancer diagnoses in 2025—the report estimates that MASLD rates may more than double by 2040, impacting over 55% of adults.
Identifying Risk Factors for Liver Cancer
Dr. El-Serag observed that early detection and effective management of MASLD could lower the risk of obesity-related liver cancer. He mentioned that weight loss is a common recommendation, noting that GLP-1 weight loss medications like Ozempic and Wegovy show promise. In a recent clinical trial, Wegovy helped about two-thirds of patients with MASH.
However, he emphasized that screening for MASLD is not as routine as it is for viral hepatitis. Dr. Arun Jesudian, a hepatologist with Weill Cornell Medicine, explained that patients are often tested for MASLD or MASH primarily when elevated liver enzymes are detected.
Increasing awareness of MASLD among both healthcare providers and patients could enhance testing and diagnoses. Jesudian remarked, “It’s vital for providers to recognize the liver disease aspect of metabolic syndrome,” which includes conditions such as high blood sugar, hypertension, and obesity.
Given that MASLD and MASH often show no symptoms, self-diagnosis can be quite difficult. “The current situation is a bit random; some get tested while others might not even be suspected at all,” Dr. El-Serag added.
Dr. Neehar Parikh from the University of Michigan noted a rise in patients with MASLD as a contributor to liver cancer. He pointed out that individuals with MASLD can develop liver cancer without cirrhosis, complicating early detection. In fact, the report claims that up to 40% of liver cancers related to MASLD occur without prior cirrhosis.
Determining who might fall into this category presents a challenge. “How do we identify these patients? That’s the big question,” Parikh stated. He added, however, that such cases are still relatively uncommon.
In conclusion, Dr. Jesudian emphasized that early treatment of liver diseases is crucial for preventing liver cancer, as it typically arises in the context of chronic liver conditions.
